Management of Anaplastic Large Cell Lymphoma.
Anaplastic large cell lymphoma (ALCL) is one of the most common peripheral T-cell lymphomas, and the incidence is higher in blacks than non-Hispanic whites. ALK-positive and ALK-negative ALCL are distinct subtypes that have different characteristics and clinical outcomes. Breast implant-associated ALCL is a rare lymphoma that has a good survival outcome, and a recent study showed that total capsulectomy is essential for treatment. Brentuximab vedotin (BV) is a standard treatment for relapsed/refractory ALCL. The response rate is high at 80-90%; however, once the disease progresses in patients on BV, survival outcome is very poor, with a median overall survival of less than two months.
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard Unit 429, Houston, TX 77030, USA; Department of Internal Medicine, The University of New Mexico, MSC10 5550, 1 University of New Mexico, Albuquerque, NM 87131, USA.
Dai
D
Chihara
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard Unit 429, Houston, TX 77030, USA. Electronic address: mfanale@mdanderson.org.
Michelle A
MA
Fanale
D018427:Breast Implants / Q000009:adverse effects; D000079963:Brentuximab Vedotin; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000627:therapeutic use*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy* / Q000208:ethnology / Q000401:mortality*; D008297:Male; D015996:Survival Rate
D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
Anaplastic large-cell lymphoma; Brentuximab vedotin; Stem cell transplant; Treatment